GLP-1 coverage in British Columbia

BC PharmaCare, delivered through the income-tested Fair PharmaCare plan, can cover semaglutide products such as Ozempic when they're prescribed for type 2 diabetes and the person meets the plan's clinical criteria. Coverage under Fair PharmaCare works through an income-based deductible: your household net income determines how much you pay out of pocket before PharmaCare starts contributing, and how much it covers after that.

Because Fair PharmaCare is deductible-based rather than a flat copay, two BC households paying for the same prescription can see very different net costs depending on income. If you're covered, it's worth checking your current deductible status through your PharmaCare account before assuming a medication is either fully covered or fully out of pocket.

PharmaCare is explicit that it does not consider semaglutide, or any other GLP-1 medication, a weight-loss benefit. Its formulary listings tie coverage to a diabetes diagnosis and associated clinical criteria, not to body weight or a weight-related indication. This mirrors the position of every other public drug plan in Canada: as of today, no provincial plan pays for a GLP-1 prescribed specifically for weight management.

In practice, this means a prescription for Wegovy or Saxenda written for weight loss, or an off-label Ozempic prescription for the same purpose, is not something Fair PharmaCare will reimburse, regardless of income tier or deductible status. Coverage rules can and do change, so if this matters to your household, it's worth confirming current criteria directly with PharmaCare rather than relying on last year's rules.

Roughly 31% of employer-sponsored private drug plans across Canada now include some coverage for GLP-1 medications prescribed for weight loss, and BC employees are no exception to that trend. Coverage varies widely by employer and plan design: some plans cap annual GLP-1 spending, some require prior authorization or a body mass index threshold, and others exclude weight-loss indications entirely while still covering the same drug for diabetes.

If you have workplace benefits, the fastest way to find out where you stand is to call your plan administrator or check your plan booklet for GLP-1, semaglutide, or 'weight management drug' language, rather than assuming coverage either way.

For BC residents without coverage for a given GLP-1 prescription, dispensing venue makes a real difference to the final price. Costco Pharmacy, which does not require a Costco membership to fill a prescription, has been offering generic semaglutide since Apotex and Dr. Reddy's launched Canadian generic versions in May 2026, at roughly $88/mo in British Columbia.

Brand-name options remain considerably more expensive at retail pharmacies: Ozempic typically runs $250 to $310/mo, Wegovy $400 to $570/mo, Mounjaro $280 to $550/mo, and Zepbound $435 to $550/mo, depending on dose and pharmacy. These figures are list prices before any insurance, savings card, or manufacturer program is applied.

A few levers can meaningfully reduce what a BC resident pays. First, ask your pharmacist or physician whether generic semaglutide is an appropriate substitute where clinically equivalent, since it prices well below brand Ozempic or Wegovy. Second, check whether your prescription qualifies under Fair PharmaCare's diabetes criteria even if you also have private coverage, since combining public and private benefits can lower your net cost.

Third, manufacturer savings programs exist for brand products: Novo Nordisk's Ozempic savings card and WegovyCare program, and Eli Lilly's myMounjaro (roughly $185/mo with eligible coverage) and LillyConnect Zepbound copay card (as low as $25/mo) can reduce brand pricing, though most of these programs require you to already have private insurance to qualify for the lowest tiers. Compounded semaglutide or tirzepatide products are not a legal option in Canada and are not addressed by any of the above; they fall outside Health Canada's regulatory framework entirely.